Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 73 publications
Cross-study analyses of the ropeginterferon alfa-2b effect on phlebotomy in low- and high-risk patients with polycythemia vera.
Journal: Leukemia & lymphoma
Published: July 17, 2026
Long term outcomes of idasanutlin therapy in hydroxyurea-refractory polycythemia vera patients.
Journal: Leukemia & lymphoma
Published: May 18, 2026
Between the classic hit and the modern sequel: transition dosing between peginterferon alfa-2a and ropeginterferon alfa-2b for myeloproliferative neoplasms.
Journal: Annals of hematology
Published: April 27, 2026
Risk of Thromboembolic Events in Patients With Polycythemia Vera: A Real-World Observational Study.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 03, 2026
Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET).
Journal: Lancet regional health. Americas
Published: March 25, 2026
POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.
Journal: Future oncology (London, England)
Published: March 07, 2026
Why JAK2-mutated neutrophils deserve to be on center stage in polycythemia vera.
Journal: Annals of hematology
Published: December 21, 2025
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients Aged 65 Years and Above With Myelofibrosis.
Journal: Clinical lymphoma, myeloma & leukemia
Published: July 08, 2025
Last Updated: 09/26/2026